Octave

Today marks an important milestone for Octave and for the MS community.

We’re excited to share a new collaboration with Quest Diagnostics, unlocking nationwide access to the Octave® MSDA Test through ~7,000 Quest patient service centers and in-office phlebotomists across the U.S.

This collaboration reflects what matters most: making proactive, precise MS care easier to deliver and easier for patients to access.

For clinicians, it removes friction from ordering and access while providing objective, clinically validated insights that strengthen treatment decisions, all so patients can navigate their MS journey with less burden and more clarity and control.

Partnering with a trusted national leader like Quest Diagnostics reinforces our shared commitment to a higher standard of care for people living with MS.

👉 Read the full announcement: https://lnkd.in/gGaQJx6p

We want to extend our thanks to everyone who visited the Octave team, engaged in insightful conversations, and made ACTRIMS Forum 2024 exceptional!
It was a pleasure to connect with attendees and share how Octave's Multiple Sclerosis Disease Activity ( ) Test, the first-and-only multivariate biomarker blood test is delivering actionable insights for more confident management.
Octave is proud to have had seven company and partner posters featured at the event. Check out all of Octave's posters by visiting https://www.octavebio.com/actrims-2024-post-event/

Octave is excited to be a part of 2024! ✈️

Join us at the ninth annual ACTRIMS event, February 29 – March 2 in West Palm Beach, Florida to learn how we are changing the paradigm of care in (MS) with our MS Solution.

➡️ Stop by Pod #631 at or schedule your meeting: https://www.octavebio.com/actrims2024-pre-event/